Notice for tafenoquine (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
tafenoquine
Date of review outcome
Lapse date
Type
Orphan drug
Indication
indicated for the radical cure (prevention of relapse) ofPIasmodium vivax (P. vivax) malaria in patients aged 6 months and older (weighing >. 5 kg) who are receiving appropriate antimalarial therapy for the acute P.vivax infection